ATE489370T1 - Herstellung und verwendung von verbindungen als aspartylproteasehemmer - Google Patents

Herstellung und verwendung von verbindungen als aspartylproteasehemmer

Info

Publication number
ATE489370T1
ATE489370T1 AT06784809T AT06784809T ATE489370T1 AT E489370 T1 ATE489370 T1 AT E489370T1 AT 06784809 T AT06784809 T AT 06784809T AT 06784809 T AT06784809 T AT 06784809T AT E489370 T1 ATE489370 T1 AT E489370T1
Authority
AT
Austria
Prior art keywords
compounds
preparation
protease inhibitors
aspartyl protease
aspartyl
Prior art date
Application number
AT06784809T
Other languages
English (en)
Inventor
Brian Mckittrick
Zhaoning Zhu
Andrew Stamford
Elizabeth Smith
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37388420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE489370(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE489370T1 publication Critical patent/ATE489370T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/72—Heterocyclic compounds containing 1,3,5-triazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06784809T 2005-06-14 2006-06-12 Herstellung und verwendung von verbindungen als aspartylproteasehemmer ATE489370T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69041305P 2005-06-14 2005-06-14
PCT/US2006/022920 WO2006138266A2 (en) 2005-06-14 2006-06-12 The preparation and use of compounds as aspartyl protease inhibitors

Publications (1)

Publication Number Publication Date
ATE489370T1 true ATE489370T1 (de) 2010-12-15

Family

ID=37388420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06784809T ATE489370T1 (de) 2005-06-14 2006-06-12 Herstellung und verwendung von verbindungen als aspartylproteasehemmer

Country Status (16)

Country Link
US (1) US8110682B2 (de)
EP (2) EP1896430B1 (de)
JP (1) JP4859922B2 (de)
KR (1) KR20080015861A (de)
CN (1) CN101198597B (de)
AR (1) AR054510A1 (de)
AT (1) ATE489370T1 (de)
AU (1) AU2006259574A1 (de)
CA (1) CA2610829A1 (de)
DE (1) DE602006018456D1 (de)
IL (1) IL187453A0 (de)
MX (1) MX2007016177A (de)
PE (1) PE20070115A1 (de)
TW (1) TW200716574A (de)
WO (1) WO2006138266A2 (de)
ZA (1) ZA200710342B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
ATE482214T1 (de) * 2005-06-14 2010-10-15 Schering Corp Aspartylproteasehemmer
WO2006138264A2 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
US8722708B2 (en) 2005-06-14 2014-05-13 Merck Sharp & Dohme Inc. Substituted isoindolines as aspartyl protease inhibitors
CN101296926A (zh) 2005-10-27 2008-10-29 先灵公司 天冬氨酰蛋白酶抑制剂
CA2653650A1 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
CN101848897A (zh) 2007-09-06 2010-09-29 先灵公司 γ分泌酶调节剂
US8487099B2 (en) 2007-11-05 2013-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2009076352A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
JP5503663B2 (ja) 2008-11-13 2014-05-28 メルク・シャープ・アンド・ドーム・コーポレーション ガンマセクレターゼモジュレータ
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
AU2009330233A1 (en) 2008-12-22 2011-07-07 Merck Sharp & Dohme Corp. Gamma secretase modulators
EP2379566A2 (de) 2008-12-22 2011-10-26 Schering Corporation Modulatoren von gamma-sekretase
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
US20120245158A1 (en) 2009-06-16 2012-09-27 Xianhai Huang Gamma secretase modulators
EP2443118A1 (de) 2009-06-16 2012-04-25 Schering Corporation Gammasekretasemodulatoren
EP2281824A1 (de) 2009-08-07 2011-02-09 Noscira, S.A. Furan-Imidazolon-Derivate zur Behandlung von kognitiven, neurodegenerativen oder neuronalen Erkrankungen oder Funktionsstörungen
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
US9284296B2 (en) 2010-11-22 2016-03-15 Aubergine Pharmaceuticals Llc Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
EP2694521B1 (de) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidin-kondensierte thiadiazindioxidverbindungen als bace-hemmer, zusammensetzungen daraus und ihre verwendung
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
ES2745539T3 (es) 2012-03-19 2020-03-02 Buck Inst Res Aging Inhibidores de BACE específicos de APP (ASBI) y uso de los mismos
EP2908825B1 (de) 2012-10-17 2018-04-18 Merck Sharp & Dohme Corp. Tricyclische substituierte thiadiazindioxidverbindungen als bace-hemmer, zusammensetzungen und deren verwendung
WO2014062553A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP3653609B1 (de) 2013-02-12 2024-04-03 Buck Institute for Research on Aging Hydantoine als modulatoren von bace-vermittelter app-verarbeitung
EP2781919A1 (de) 2013-03-19 2014-09-24 Roche Diagniostics GmbH Verfahren/Vorrichtung zur Erzeugung eines korrigierten Werts einer Analytenkonzentration in einer Körperflüssigkeitsprobe
US9745324B2 (en) 2013-12-18 2017-08-29 Merck Sharp & Dohme Corp. Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
EP3571193B1 (de) 2017-01-23 2021-12-01 Cadent Therapeutics, Inc. Kaliumkanalmodulatoren
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
MX2021004647A (es) 2018-10-22 2021-08-16 Novartis Ag Formas cristalinas de moduladores de los canales de potasio.
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1077204A (en) 1912-11-20 1913-10-28 John Bonner Semple Tracer for projectiles.
US3287365A (en) * 1963-12-24 1966-11-22 American Cyanamid Co Novel dihydro-s-triazines and method of preparation
US3287366A (en) * 1963-12-24 1966-11-22 American Cyanamid Co Novel 1, 2-dihydro-s-triazines
US3876785A (en) * 1967-12-06 1975-04-08 Beecham Group Ltd 4,6-diamino-1,2-dihydro-arylmethoxy-1,3,5-triazines for combating plasmodium parasites
GB1217415A (en) * 1968-07-04 1970-12-31 Vitamins Ltd Triazine derivatives and pharmaceutical formulation and processes for making same
US3723429A (en) * 1969-11-06 1973-03-27 Beecham Group Ltd Di-hydro triazine derivatives
US3682912A (en) * 1969-12-18 1972-08-08 Beecham Group Ltd Di-hydro triazine derivatives
US6232309B1 (en) * 1989-03-09 2001-05-15 Nihon Bayer Agrochem K.K. Insecticidal heterocyclic compounds
WO1993004047A1 (en) 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5565451A (en) * 1994-09-15 1996-10-15 Fmc Corporation 1-substituted-2, 4-diamino-6, 6-dialkyl-1, 6-dihydro-1, 3, 5-triazines as insecticides
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5935958A (en) 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
DE69928282T2 (de) * 1998-12-01 2006-06-29 Bayer Cropscience Ag Substituierte 1,3,5-triazine als herbizide
US6294554B1 (en) 1999-09-22 2001-09-25 Schering Corporation Muscarinic antagonists
GB0001565D0 (en) * 2000-01-24 2000-03-15 Isis Innovation Dihydrofolate reductase inhibitors
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
AU2001264385A1 (en) * 2000-07-07 2002-01-21 Lg Life Sciences Ltd Novel cephalosporin compounds and process for preparing the same
AU2002235224A1 (en) 2000-12-22 2002-07-08 Schering Corporation Muscarinic antagonists
US7560482B2 (en) 2001-03-15 2009-07-14 The Johns Hopkins University Inhibitors of plasmepsins
GB0123467D0 (en) * 2001-09-28 2001-11-21 Hoffmann La Roche Carbocyclic HIV Protease inhibitors
MXPA04003298A (es) 2001-10-10 2004-07-23 Schering Corp Compuestos de piperidina como antagonistas muscarinicos.
AU2002335607A1 (en) * 2002-09-06 2004-03-29 Infineon Technologies Ag Method and system for determining conformance of a data key with rules by means of memory lookups
AU2003278904A1 (en) * 2002-09-24 2004-04-19 Kornis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
US7256218B2 (en) * 2002-11-22 2007-08-14 Jacobus Pharmaceutical Company, Inc. Biguanide and dihydrotriazine derivatives
US7622469B2 (en) * 2002-12-17 2009-11-24 Hamari Chemicals, Ltd. 2,4-diamino-1,3,5-triazine derivatives
SG146624A1 (en) * 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US20050123906A1 (en) * 2003-11-06 2005-06-09 Rana Tariq M. Protein modulation
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
MXPA06005658A (es) * 2004-04-27 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de micofenolato mofetil, y otros esteres de acido micofenolico.
CA2578600A1 (en) 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
CA2579724A1 (en) 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
WO2006044497A2 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
WO2006044492A2 (en) 2004-10-14 2006-04-27 Ingenious Targeting Laboratory, Inc. Methods for generating rat embryo-derived cell lines and genetic modification of rat genome
US20090221579A1 (en) 2004-10-15 2009-09-03 Jeffrey Scott Albert Substituted Amino-Compounds and Uses Thereof

Also Published As

Publication number Publication date
MX2007016177A (es) 2008-03-07
PE20070115A1 (es) 2007-02-13
CN101198597B (zh) 2011-11-16
AR054510A1 (es) 2007-06-27
US20070010667A1 (en) 2007-01-11
KR20080015861A (ko) 2008-02-20
WO2006138266A3 (en) 2007-03-08
US8110682B2 (en) 2012-02-07
IL187453A0 (en) 2008-02-09
AU2006259574A1 (en) 2006-12-28
EP1896430B1 (de) 2010-11-24
CN101198597A (zh) 2008-06-11
EP2194047A1 (de) 2010-06-09
DE602006018456D1 (de) 2011-01-05
CA2610829A1 (en) 2006-12-28
WO2006138266A2 (en) 2006-12-28
JP2008546697A (ja) 2008-12-25
ZA200710342B (en) 2008-12-31
EP1896430A2 (de) 2008-03-12
TW200716574A (en) 2007-05-01
JP4859922B2 (ja) 2012-01-25

Similar Documents

Publication Publication Date Title
DE602006018456D1 (de) Herstellung und verwendung von verbindungen als aspartylproteasehemmer
ATE492545T1 (de) Verbindungen und zusammensetzungen als proteinkinase-hemmer
ATE455093T1 (de) Herstellung von pregabalin und verwandten verbindungen
DE602005019971D1 (de) Inhibitoren von cysteinprotease
EP1755661A4 (de) Verwendung von gelsolin zur behandlung von infektionen
ATE470660T1 (de) Schwefelverbindungen als inhibitoren der ns3- serinprotease des hepatitis-c-virus
ATE477249T1 (de) Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
EP2125870A4 (de) Inhibitoren von hepatitis-c-ns3-protease
EP1874239A4 (de) Halb angetriebenes exoskelett der unteren extremität
ATE428424T1 (de) 1-benzoyl-piperazin-derivate als glycin- aufnahmehemmer zur behandlung von psychosen
ATE502951T1 (de) Verbindungen und zusammensetzungen als kanalaktivierende protease-hemmer
DE602006009280D1 (de) Inhibitoren der hcv-ns3-protease
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
DK1888584T3 (da) Tricykliske 1,6-dihydro- 1,3,5,6-tetraaza-as-indacen-baserede forbindelser og farmaceutiske sammensætninger omfattende samme som hæmmere af IKK-enzymaktivitet
ATE493174T1 (de) Verbindungen und zusammensetzungen als kanal- aktivierende proteasehemmer
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
ATE405553T1 (de) Heterocyclische verbindungen als inhibitoren von faktor viia
DE602006004463D1 (de) Kristallform von asenapinmaleat
DE602006013878D1 (de) Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
ATE521365T1 (de) Kinin-antagonisten zur behandlung von blasenfunktionsstörung
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
EA200601568A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
ATE512141T1 (de) Verwendung von tetrahydrobenzoxazinen als antioxidantien
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties